Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number...

Full description

Bibliographic Details
Main Authors: Michael B. Atkins, David F. McDermott, David I. Quinn, Thomas Olencki, Thomas Hutson, Brian I. Rini, Laura S. Wood, Martin H. Voss, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Allan J. Pantuck, Virginia Seery, Christopher G. Wood
Format: Article
Language:English
Published: BMJ Publishing Group 2016-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/4/1/81.full

Internet

https://jitc.bmj.com/content/4/1/81.full

Similar Items